NasdaqGM - Nasdaq Real Time Price USD

Sage Therapeutics, Inc. (SAGE)

6.61

+0.23

+(3.61%)

At close: May 15 at 4:00:00 PM EDT

6.65

+0.04

+(0.61%)

Pre-Market: 8:00:02 AM EDT

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y

SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.

Zacks 15 days ago

SAGE
+3.61%

BIIB
Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ...

Sage Therapeutics Inc (SAGE) reports significant growth in ZURZUVAE prescriptions and collaboration revenue, alongside a substantial reduction in R&D expenses.

GuruFocus.com 16 days ago

SAGE
+3.61%
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -2.02% and 0.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 16 days ago

SAGE
+3.61%
Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

CAMBRIDGE, Mass., April 29, 2025--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025.

Business Wire 16 days ago

SAGE
+3.61%
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 21 days ago

AGIO

SAGE
+3.61%
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 23 days ago

SAGE
+3.61%
Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

CAMBRIDGE, Mass., April 15, 2025--Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 2025 financial results and discuss recent business updates.

Business Wire last month

SAGE
+3.61%
Sage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?

Sage Therapeutics (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 2 months ago

SAGE
+3.61%

VKTX
Sage Therapeutics Announces R&D Leadership Transition

CAMBRIDGE, Mass., March 04, 2025--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company’s product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an

Business Wire 2 months ago

SAGE
+3.61%
Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Sage Therapeutics, Inc. (NASDAQ:SAGE) stands against the other psychedelic stocks. The Therapeutic Potential and Investment Boom in Psychedelic Medicine In contrast to drugs like cocaine or marijuana, psychedelics are […]

Insider Monkey 2 months ago

SAGE
+3.61%
Is Sage Therapeutics, Inc. (SAGE) the Best Small-Cap Growth Stock to Buy Now?

We recently published a list of 10 Best Small-Cap Growth Stocks to Buy Now. In this article, we are going to take a look at where Sage Therapeutics, Inc. (NASDAQ:SAGE) stands against other best small-cap growth stocks to buy now. Are Small-Cap Stocks Poised for Growth? On November 4, 2024, Nick Sheridan, Portfolio Manager at […]

Insider Monkey 2 months ago

SAGE
+3.61%
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

Scotiabank lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps an Outperform rating on the shares. The firm’s rating remains Outperform based on its belief that the company will be sold to Biogen (BIIB) at a significant premium, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on SAGE: Sage Therapeutics price target lowere

TipRanks 2 months ago

BIIB

SAGE
+3.61%
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y

SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.

Zacks 2 months ago

SAGE
+3.61%

BIIB
Q4 2024 SAGE Therapeutics Inc Earnings Call

Q4 2024 SAGE Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

SAGE
+3.61%

BIIB
Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ...

Sage Therapeutics Inc (SAGE) reports significant prescription growth for ZURZUVAE, despite a net loss and strategic uncertainties.

GuruFocus.com 3 months ago

SAGE
+3.61%
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -7.59% and 11.20%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

SAGE
+3.61%
Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

CAMBRIDGE, Mass., February 11, 2025--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024.

Business Wire 3 months ago

SAGE
+3.61%
Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 3 months ago

SAGE
+3.61%

ILMN
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics are part of the Zacks top Analyst Blog.

Zacks 3 months ago

BIIB

SAGE
+3.61%

AKRO
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

SAGE and AKRO are up this week on regulatory and pipeline updates.

Zacks 3 months ago

SAGE
+3.61%

BIIB

CYTK

Performance Overview

Return	SAGE	S&P 500 (^GSPC)
YTD	+21.73%	+0.60%
1-Year	-43.55%	+11.47%
3-Year	-78.48%	+47.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sage Therapeutics, Inc. (SAGE)

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y

Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ...

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

Sage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?

Sage Therapeutics Announces R&D Leadership Transition

Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025

Is Sage Therapeutics, Inc. (SAGE) the Best Small-Cap Growth Stock to Buy Now?

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y

Q4 2024 SAGE Therapeutics Inc Earnings Call

Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ...

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates

Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

Performance Overview